An update from Annexon Biosciences (ANNX) is now available.
Annexon’s Phase 3 clinical trial of ANX005 in GBS patients yielded promising results, with the drug showing a significant improvement on the GBS-disability scale and other key secondary outcomes, such as muscle strength and reduced need for artificial ventilation. The study, conducted in areas with higher GBS prevalence and limited treatment access, supports the drug’s safety and paves the way for real-world evidence collection and FDA submission. These developments hold potential for addressing the substantial healthcare burden of GBS, a condition currently lacking FDA-approved treatments.
For detailed information about ANNX stock, go to TipRanks’ Stock Analysis page.
